Koyfin Home > Directory > Health Care > Aerie Pharmaceuticals > Total Debt / (EBITDA-CAPEX)

Aerie Pharmaceuticals Total Debt / (EBITDA-CAPEX) Chart (AERI)

Aerie Pharmaceuticals annual/quarterly Total Debt / (EBITDA-CAPEX) from 2012 to 2020.
  • Aerie Pharmaceuticals Total Debt / (EBITDA-CAPEX) for the quarter ending June 06, 2020 was $-2m a 21.68% decrease of 0m year over year
  • Aerie Pharmaceuticals Total Debt / (EBITDA-CAPEX) for the last 12 months ending June 06, 2020 was $-1m a 18.97% decrease of 0m year over year
  • Aerie Pharmaceuticals Annual Total Debt / (EBITDA-CAPEX) for 2019 was $-1m a 35.93% decrease of 0m from 2018
  • Aerie Pharmaceuticals Annual Total Debt / (EBITDA-CAPEX) for 2017 was $-1m a -68.37% increase of 0m from 2016
  • Aerie Pharmaceuticals Annual Total Debt / (EBITDA-CAPEX) for 2016 was $-1m a -28.95% increase of 0m from 2015
Other Ratios Metrics:
  • Aerie Pharmaceuticals Total Debt / Capital for the quarter ending June 06, 2018 was $39m a -12.45% decrease of -5m year over year
  • Aerie Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $6m a 11.47% increase of 1m year over year
  • Aerie Pharmaceuticals Total Debt / Equity for the quarter ending June 06, 2018 was $64m a -22.13% decrease of -14m year over year
View Chart On Koyfin

Quarterly AERI Total Debt / (EBITDA-CAPEX) Data

06/2020$-2m
03/2020$-1m
12/2019$-1m
09/2019$-1m
06/2019$0m
03/2019$0m
06/2018$0m
03/2018$-1m
12/2017$0m
09/2017$-1m

Annual AERI Total Debt / (EBITDA-CAPEX) Data

2019$-1m
2017$-1m
2016$-1m
2015$-2m
2014$-2m
2012$0m